Avidity Biosciences (RNA) Stock Forecast & Price Target

Compare

1,038 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RNA Analyst Ratings

Strong Buy

18 Buy

0 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Avidity

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RNA Stock 12 Month Forecast

Average Price Target

$67.24

▲(87.19%Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $67.24 with a high forecast of $96.00 and a low forecast of $50.00. The average price target represents a 87.19% change from the last price of $35.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","43":"$43","61":"$61","79":"$79","97":"$97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,43,61,79,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.46,33.65538461538462,38.85076923076923,44.04615384615384,49.24153846153846,54.43692307692308,59.63230769230769,64.8276923076923,70.02307692307693,75.21846153846153,80.41384615384615,85.60923076923078,90.80461538461537,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.46,31.443076923076923,34.426153846153845,37.40923076923077,40.39230769230769,43.37538461538461,46.35846153846154,49.34153846153846,52.324615384615385,55.30769230769231,58.29076923076923,61.27384615384615,64.25692307692307,{"y":67.24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.46,30.11692307692308,31.773846153846154,33.43076923076923,35.08769230769231,36.744615384615386,38.401538461538465,40.05846153846154,41.715384615384615,43.37230769230769,45.02923076923077,46.68615384615384,48.34307692307692,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.28,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$96.00

Average Price Target$67.24

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$38

Hold

5.79%

Upside

Reiterated

07/26/25

The overall stock score reflects a mix of strengths and challenges. The company's recent regulatory milestones and positive market momentum are significant positives. However, financial performance, including negative earnings and cash flow struggles, weighs down the score. Valuation concerns due to negative earnings further impact the overall assessment.

Corinne JohnsonGoldman Sachs

Goldman Sachs

―

Buy

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Tazeen AhmadBank of America Securities

Bank of America Securities

$54

Buy

50.33%

Upside

Reiterated

07/14/25

Avidity Biosciences Positioned for Leadership in Muscular Dystrophy with Strategic Regulatory Advancements

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$60→$70

Buy

94.88%

Upside

Reiterated

07/11/25

Avidity Biosciences price target raised to $70 from $60 at Evercore ISIAvidity Biosciences price target raised to $70 from $60 at Evercore ISI

Yanan ZhuWells Fargo

Wells Fargo

$70

Buy

94.88%

Upside

Reiterated

07/10/25

Avidity Biosciences: Promising Advancements and Strategic Positioning Drive Buy Rating

Eric Schmidt FCACantor Fitzgerald

Cantor Fitzgerald

$96

Buy

167.26%

Upside

Reiterated

06/27/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

Ritu BaralTD Cowen

TD Cowen

$78

Buy

117.15%

Upside

Reiterated

06/24/25

Avidity Biosciences (RNA) Gets a Buy from TD Cowen

Gena WangBarclays

Barclays

$59

Buy

64.25%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA) and Exelixis (NASDAQ: EXEL)

William PickeringBernstein

Bernstein

$50

Buy

39.20%

Upside

Initiated

06/23/25

Avidity Biosciences (RNA) Has a New Rating from Bernstein

Andy ChenWolfe Research

Wolfe Research

$55

Buy

53.12%

Upside

Initiated

06/16/25

Avidity Biosciences initiated with an Outperform at Wolfe ResearchAvidity Biosciences initiated with an Outperform at Wolfe Research

Joseph SchwartzLeerink Partners

Leerink Partners

$60→$65

Buy

80.96%

Upside

Reiterated

06/13/25

Avidity Biosciences price target raised to $65 from $60 at LeerinkAvidity Biosciences price target raised to $65 from $60 at Leerink

Martin AusterRaymond James

Raymond James

$65

Buy

80.96%

Upside

Initiated

06/10/25

Avidity Biosciences initiated with a Strong Buy at Raymond JamesAvidity Biosciences initiated with a Strong Buy at Raymond James

Geoff MeachamCiti

Citi

$70→$75

Buy

108.80%

Upside

Reiterated

06/10/25

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA), Danaher (NYSE: DHR) and Ascendis Pharma (NASDAQ: ASND)

Louise ChenScotiabank

Scotiabank

$70

Buy

94.88%

Upside

Reiterated

06/10/25

Avidity Biosciences (RNA) Receives a Buy from Scotiabank

Joseph StringerNeedham

Needham

$60

Buy

67.04%

Upside

Reiterated

06/09/25

Avidity Biosciences Receives Buy Rating Due to Promising FSHD Program Developments and Accelerated FDA Approval Pathway

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$38

Hold

5.79%

Upside

Reiterated

07/26/25

Corinne JohnsonGoldman Sachs

Goldman Sachs

―

Buy

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Tazeen AhmadBank of America Securities

Bank of America Securities

$54

Buy

50.33%

Upside

Reiterated

07/14/25

Avidity Biosciences Positioned for Leadership in Muscular Dystrophy with Strategic Regulatory Advancements

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$60→$70

Buy

94.88%

Upside

Reiterated

07/11/25

Avidity Biosciences price target raised to $70 from $60 at Evercore ISIAvidity Biosciences price target raised to $70 from $60 at Evercore ISI

Yanan ZhuWells Fargo

Wells Fargo

$70

Buy

94.88%

Upside

Reiterated

07/10/25

Avidity Biosciences: Promising Advancements and Strategic Positioning Drive Buy Rating

Eric Schmidt FCACantor Fitzgerald

Cantor Fitzgerald

$96

Buy

167.26%

Upside

Reiterated

06/27/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

Ritu BaralTD Cowen

TD Cowen

$78

Buy

117.15%

Upside

Reiterated

06/24/25

Avidity Biosciences (RNA) Gets a Buy from TD Cowen

Gena WangBarclays

Barclays

$59

Buy

64.25%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA) and Exelixis (NASDAQ: EXEL)

William PickeringBernstein

Bernstein

$50

Buy

39.20%

Upside

Initiated

06/23/25

Avidity Biosciences (RNA) Has a New Rating from Bernstein

Andy ChenWolfe Research

Wolfe Research

$55

Buy

53.12%

Upside

Initiated

06/16/25

Avidity Biosciences initiated with an Outperform at Wolfe ResearchAvidity Biosciences initiated with an Outperform at Wolfe Research

Joseph SchwartzLeerink Partners

Leerink Partners

$60→$65

Buy

80.96%

Upside

Reiterated

06/13/25

Avidity Biosciences price target raised to $65 from $60 at LeerinkAvidity Biosciences price target raised to $65 from $60 at Leerink

Martin AusterRaymond James

Raymond James

$65

Buy

80.96%

Upside

Initiated

06/10/25

Avidity Biosciences initiated with a Strong Buy at Raymond JamesAvidity Biosciences initiated with a Strong Buy at Raymond James

Geoff MeachamCiti

Citi

$70→$75

Buy

108.80%

Upside

Reiterated

06/10/25

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA), Danaher (NYSE: DHR) and Ascendis Pharma (NASDAQ: ASND)

Louise ChenScotiabank

Scotiabank

$70

Buy

94.88%

Upside

Reiterated

06/10/25

Avidity Biosciences (RNA) Receives a Buy from Scotiabank

Joseph StringerNeedham

Needham

$60

Buy

67.04%

Upside

Reiterated

06/09/25

Avidity Biosciences Receives Buy Rating Due to Promising FSHD Program Developments and Accelerated FDA Approval Pathway

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avidity Biosciences

1 Month

xxx

Success Rate

14/24 ratings generated profit

Average Return

+3.87%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +3.87% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+12.29%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +12.29% per trade.

1 Year

Ritu BaralTD Cowen

Success Rate

9/14 ratings generated profit

Average Return

+89.99%

reiterated a buy rating last month

Copying Ritu Baral's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +89.99% per trade.

2 Years

xxx

Success Rate

20/23 ratings generated profit

Average Return

+123.08%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.96% of your transactions generating a profit, with an average return of +123.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RNA Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RNA has received 35 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. RNA average Analyst price target in the past 3 months is 67.24.

Each month's total comprises the sum of three months' worth of ratings.

RNA Financial Forecast

RNA Earnings Forecast

Next quarter’s earnings estimate for RNA is -$0.96 with a range of -$1.33 to -$0.55. The previous quarter’s EPS was -$0.90. RNA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.11% of the time in the same period. In the last calendar year RNA has Preformed in-line its overall industry.

RNA Sales Forecast

Next quarter’s sales forecast for RNA is $1.49M with a range of $0.00 to $3.89M. The previous quarter’s sales results were $1.57M. RNA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.98% of the time in the same period. In the last calendar year RNA has Preformed in-line its overall industry.

RNA Stock Forecast FAQ

What is RNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Avidity Biosciences Inc’s 12-month average price target is 67.24.

What is RNA’s upside potential, based on the analysts’ average price target?

Avidity Biosciences Inc has 87.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RNA a Buy, Sell or Hold?

Avidity Biosciences Inc has a consensus rating of Strong Buy which is based on 18 buy ratings, 0 hold ratings and 0 sell ratings.

What is Avidity Biosciences Inc’s price target?

The average price target for Avidity Biosciences Inc is 67.24. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $96.00 ,the lowest forecast is $50.00. The average price target represents 87.19% Increase from the current price of $35.92.

What do analysts say about Avidity Biosciences Inc?

Avidity Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of RNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Avidity Biosciences (RNA) Stock Forecast & Price Target

RNA Analyst Ratings

RNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avidity Biosciences

RNA Analyst Recommendation Trends

RNA Financial Forecast

RNA Earnings Forecast

RNA Sales Forecast

RNA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts